AstraZeneca Annual Report and Form 20-F Information 2011

Financial StatementsConsolidated Statement of Changes in Equityfor the year ended 31 DecemberSharecapital$mSharepremiumaccount$mCapitalredemptionreserve$mMergerreserve$mOtherreserves$mRetainedearnings$mTotal$mNoncontrollinginterests$mAt 1 January 2009 362 2,046 94 433 1,405 11,572 15,912 148 16,060Profit for the period – – – – – 7,521 7,521 23 7,544Other comprehensive income – – – – – (54) (54) – (54)Transfer to other reserves 1 – – – – (13) 13 – – –Transactions with ownersDividends – – – – – (3,026) (3,026) – (3,026)Issue of Ordinary Shares 1 134 – – – – 135 – 135Share-based payments – – – – – 172 172 – 172Transfer from non-controlling interests to payables – – – – – – – (9) (9)Dividend paid by subsidiary to non-controlling interests – – – – – – – (1) (1)Net movement 1 134 – – (13) 4,626 4,748 13 4,761At 31 December 2009 363 2,180 94 433 1,392 16,198 20,660 161 20,821Profit for the period – – – – – 8,053 8,053 28 8,081Other comprehensive income – – – – – 5 5 20 25Transfer to other reserves 1 – – – – (15) 15 – – –Transactions with ownersDividends – – – – – (3,494) (3,494) – (3,494)Issue of Ordinary Shares 2 492 – – – – 494 – 494Repurchase of Ordinary Shares (13) – 13 – – (2,604) (2,604) – (2,604)Share-based payments – – – – – 99 99 – 99Transfer from non-controlling interests to payables – – – – – – – (11) (11)Dividend paid by subsidiary to non-controlling interests – – – – – – – (1) (1)Net movement (11) 492 13 – (15) 2,074 2,553 36 2,589At 31 December 2010 352 2,672 107 433 1,377 18,272 23,213 197 23,410Profit for the period – – – – – 9,983 9,983 33 10,016Other comprehensive income – – – – – (555) (555) 9 (546)Transfer to other reserves 1 – – – – 2 (2) – – –Transactions with ownersDividends – – – – – (3,752) (3,752) – (3,752)Issue of Ordinary Shares 3 406 – – – – 409 – 409Repurchase of Ordinary Shares (32) – 32 – – (6,015) (6,015) – (6,015)Share-based payments – – – – – (37) (37) – (37)Transfer from non-controlling interests to payables – – – – – – – (9) (9)Dividend paid by subsidiary to non-controlling interests – – – – – – – (4) (4)Net movement (29) 406 32 – 2 (378) 33 29 62At 31 December 2011 323 3,078 139 433 1,379 17,894 23,246 226 23,472Totalequity$m1Amounts charged or credited to other reserves relate to exchange adjustments arising on goodwill.144 Financial StatementsAstraZeneca Annual Report and Form 20-F Information 2011